<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;
	font-weight:normal;}
a:link, span.MsoHyperlink
	{color:#0563C1;
	text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>

</head>

<body lang=EN-AU link="#0563C1" vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<h1><span lang=EN-GB style='font-size:14.0pt;line-height:107%'>2020B09 </span><span
lang=EN-GB>Discuss factors that influence the toxicity of local anaesthetics <br>
when used for topical anaesthesia of skin and mucosa.</span></h1>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>&nbsp;</span></p>

<h3><span lang=EN-GB>List:</span></h3>

<p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:22.5pt;text-indent:-13.5pt'><span lang=EN-GB
style='font-size:10.0pt;line-height:107%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:10.0pt;line-height:107%'>Means of toxicity</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:22.5pt;text-indent:-13.5pt'><span lang=EN-GB
style='font-size:10.0pt;line-height:107%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:10.0pt;line-height:107%'>Determinants of drug
uptake</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:22.5pt;text-indent:-13.5pt'><span lang=EN-GB
style='font-size:10.0pt;line-height:107%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-size:10.0pt;line-height:107%'>Determinants of LAST
susceptibility</span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>&nbsp;</span></p>

<h3><span lang=EN-GB>Means of toxicity:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>LAST</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Systemic blockade of voltage-gated Na+
  channels (</span><span lang=EN-GB style='font-size:10.0pt;font-family:"Cambria Math",serif'>&#8733;</span><span
  lang=EN-GB style='font-size:10.0pt'> dose)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>CNS effects: e.g. seizure, coma</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>CVS effects: e.g. arrhythmia, arrest</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Cocaine toxicity</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Effects mostly </span><span lang=EN-GB
  style='font-size:10.0pt;font-family:"Cambria Math",serif'>&#8733;</span><span
  lang=EN-GB style='font-size:10.0pt'> dose</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Effects ? additive ? synergistic with
  other local anesthetics (e.g. nasal surgery)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>CVS: &#8593;&#8593;noradrenaline -&gt; &#8593;BP,
  &#8593;HR, coronary vasoconstriction,<br>
  Cardiomyopathy (? idiosyncratic)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>CNS: &#8593;&#8593;dopamine -&gt; euphoria,
  risk-taking</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Nasal: profound vasoconstriction -&gt;
  ischaemic necrosis (</span><span lang=EN-GB style='font-size:10.0pt;
  font-family:"Cambria Math",serif'>&#8733;</span><span lang=EN-GB
  style='font-size:10.0pt'> dose)</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Prilocaine toxicity</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;Methaemoglobin -&gt; Hb unable to
  bind O<sub>2</sub> (</span><span lang=EN-GB style='font-size:10.0pt;
  font-family:"Cambria Math",serif'>&#8733;</span><span lang=EN-GB
  style='font-size:10.0pt'> dose)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;&#8593;Risk of reductase
  deficiency: neonate, congenital</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Hypersensitivity</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>i.e. allergy, anaphylaxis
  (dose-independent)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>e.g. PABA metabolite of esters</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>e.g. sodium metabisulfite preservative with
  lignocaine</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>&nbsp;</span></p>

<h3><span lang=EN-GB>Determinants of drug uptake:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><u><span
  lang=EN-GB style='font-size:10.0pt'>Diffusion rate:</span></u></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><i><span
  lang=EN-GB style='font-size:10.0pt'>Ficks law:</span></i></p>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'><img width=357 height=67 id="Picture 9"
  src="2020B09_topical_local_anaesthetic_toxicity_files/image001.jpg"></span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>    - &#8593;C<sub>1</sub></span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;Drug concentration (e.g. 10%
  lignocaine for airway topicalisation)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Eutectic mixture: optimal ratio -&gt; &#8595;melting
  point -&gt; liquid state -&gt; &#8593;C<sub>1</sub> (cf. solution)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>EMLA: 2.5% lignocaine + 2.5% prilocaine, melting
  point 18</span><span lang=EN-GB style='font-size:10.0pt'>°</span><span
  lang=EN-GB style='font-size:10.0pt'>C</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>    - &#8595;C<sub>2</sub></span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;Tissue blood flow -&gt; &#8595;C<sub>2</sub>
  but also offset of local effect</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Regional variation: e.g. lower flow to
  foot cf. scalp</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Drug effect: e.g. prolonged EMLA
  application -&gt; vasodilation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Drug additive: adrenaline -&gt;
  &#8595;rate of absorption (e.g. nasal lignocaine)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Pathology: hypothermia, shock, heart
  failure</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>    - &#8593;Area</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0cm;margin-right:0cm;margin-bottom:
  0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;Area of application -&gt;
  &#8593;total absorption but &#8596; absorption per unit area<br>
  e.g. multiple patches</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>    - &#8595;Thickness</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Extensor thicker than flexor</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Lower limb thicker than upper limb</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Mucous membrane -&gt; &#8595;&#8595;thickness,
  &#8593;&#8593;rate of blood flow</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>Contraindication for EMLA, topical amethocaine</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>Risk of inadvertent overdose during topicalisation
  for AFOI</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>    - &#8593;Diffusion</span></p>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>       coefficient</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;Lipid solubility -(lignocaine
  150x, prilocaine 50x procaine)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;% unionized</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>Drug: lignocaine 25%, prilocaine 33%, higher than
  most</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>Additive: NaOH in EMLA -&gt; &#8593;pH</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;Molecular weight (all LA drugs
  have similar MW 200-250g/mol)</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><u><span
  lang=EN-GB style='font-size:10.0pt'>Diffusion time:</span></u></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Uptake </span><span lang=EN-GB
  style='font-family:"Cambria Math",serif;color:#202124;background:white'>&#8733;</span><span
  lang=EN-GB style='font-size:10.0pt'> application time</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>EMLA 30 mins for PIVC, 120 mins for skin
  graft</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>2% lignocaine viscous gargle &lt; 1
  minute for pharyngeal topicalisation</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>&nbsp;</span></p>

<h3><span lang=EN-GB>Determinants of LAST susceptibility:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Drug</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><u><span
  lang=EN-GB style='font-size:10.0pt'>Pharmacokinetics (PK):</span></u></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Esters: rapid metabolism by BChE -&gt;
  short t<sub>1/2</sub></span><sub><span lang=EN-GB style='font-size:10.0pt'>&#946;</span></sub></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Amides: slow metabolism by liver -&gt;
  long t<sub>1/2</sub></span><sub><span lang=EN-GB style='font-size:10.0pt'>&#946;</span></sub></p>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><u><span
  lang=EN-GB style='font-size:10.0pt'>Pharmacodynamics (PD):</span></u></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Toxicity threshold: bupiv 1.5mcg/mL,
  ropiv 4mcg/mL, lignocaine 5mcg/mL</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>CC:CNS ratio  bupivacaine 3:1,
  ropivacaine 5:1, lignocaine 7:1</span></p>
  </td>
 </tr>
 <tr>
  <td width=113 valign=top style='width:84.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Patient</span></p>
  </td>
  <td width=488 valign=top style='width:366.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><u><span
  lang=EN-GB style='font-size:10.0pt'>PK:</span></u></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Absorption: see above</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Distribution: Cachexia -&gt;
  &#8593;plasma concentration -&gt; &#8593;risk</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Metabolism: liver disease -&gt; &#8595;rate
  of amide removal -&gt; &#8593;risk</span></p>
  <p class=MsoNormal style='margin-bottom:0cm;line-height:normal'><u><span
  lang=EN-GB style='font-size:10.0pt'>PD:</span></u></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>Class 1 antiarrhythmics -&gt; &#8593;Na<sup>+</sup>
  channel blockade -&gt; &#8593;risk</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>CVS</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;HR -&gt; &#8593;channel cycling rate -&gt; &#8593;risk</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;PaO<sub>2</sub>, &#8595;pH, &#8593;K<sup>+</sup>
  -&gt; &#8593;risk</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>IHD, channelopathy -&gt; &#8593;risk arrhythmias</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>AV conduction delay -&gt; &#8593;risk high grade
  block from lignocaine</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:12.9pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-GB style='font-size:10.0pt'>CNS</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;PaCO<sub>2</sub> (&#8593;CBF), &#8595;PaO<sub>2</sub>,
  &#8595;pH -&gt; &#8593;risk</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>Pregnancy -&gt; &#8593;local anaesthetic sensitivity</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0cm;margin-right:0cm;
  margin-bottom:0cm;margin-left:35.4pt;text-indent:-9.0pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-GB
  style='font-size:10.0pt'>Epilepsy, tramadol -&gt; &#8595;seizure threshold</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>Feedback welcome at </span><span lang=EN-GB><a
href="mailto:ketaminenightmares@gmail.com"><span style='font-size:10.0pt;
line-height:107%'>ketaminenightmares@gmail.com</span></a></span></p>

<p class=MsoNormal style='margin-bottom:0cm'><span lang=EN-GB style='font-size:
10.0pt;line-height:107%'>&nbsp;</span></p>

</div>

</body>

</html>
